<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "4: following risks actually", fill: "#1034a6"},
{source: "4: following risks actually", target: "4: financial condition", fill: "#1034a6"},
{source: "4: financial condition", target: "4: operations would suffer", fill: "#1034a6"},
{source: "4: following risks actually", target: "10: Currently ", fill: "#a76bcf"},
{source: "10: Currently ", target: "10: operations", fill: "#a76bcf"},
{source: "10: operations", target: "10: dependent", fill: "#a76bcf"},
{source: "10: dependent", target: "10: on sales license royalties", fill: "#a76bcf"},
{source: "10: on sales license royalties", target: "10: associated with transdermal", fill: "#a76bcf"},
{source: "10: Currently ", target: "14: study also seeks", fill: "#e52b50"},
{source: "14: study also seeks", target: "14: transdermal estrogen patches", fill: "#e52b50"},
{source: "14: transdermal estrogen patches", target: "14: less beneficial than", fill: "#e52b50"},
{source: "14: study also seeks", target: "15: United States ", fill: "#fad6a5"},
{source: "15: United States ", target: "15: adversely", fill: "#fad6a5"},
{source: "15: adversely", target: "15: or other HT ", fill: "#fad6a5"},
{source: "15: or other HT ", target: "15: studies find", fill: "#fad6a5"},
{source: "15: United States ", target: "16: further adverse", fill: "#f5f5f5"},
{source: "16: further adverse", target: "16: adverse impact on", fill: "#f5f5f5"},
{source: "16: adverse impact on", target: "16: financial position", fill: "#f5f5f5"},
{source: "16: financial position", target: "16: operations", fill: "#f5f5f5"},
{source: "16: further adverse", target: "27: financial resources necessary", fill: "#c0c"},
{source: "27: financial resources necessary", target: "27: dedicate resources will", fill: "#c0c"},
{source: "27: dedicate resources will", target: "27: successfully", fill: "#c0c"},
{source: "27: successfully", target: "27: regulatory approval", fill: "#c0c"},
{source: "27: regulatory approval", target: "27: approved product", fill: "#c0c"},
{source: "27: approved product", target: "27: quantities at reasonable costs", fill: "#c0c"},
{source: "27: quantities at reasonable costs", target: "27: successfully marketed either by us", fill: "#c0c"},
{source: "27: successfully marketed either by us", target: "27: licensing partner", fill: "#c0c"},
{source: "27: financial resources necessary", target: "31: intellectual", fill: "#b39eb5"},
{source: "31: intellectual", target: "31: manufacture", fill: "#b39eb5"},
{source: "31: manufacture", target: "31: commercialize", fill: "#b39eb5"},
{source: "31: intellectual", target: "35: particular product", fill: "#ff0"},
{source: "35: particular product", target: "35: agreement on", fill: "#ff0"},
{source: "35: agreement on", target: "35: commercially reasonable terms", fill: "#ff0"},
{source: "35: particular product", target: "49: of the Novogyne ", fill: "#36454f"},
{source: "49: of the Novogyne ", target: "49: joint venture", fill: "#36454f"},
{source: "49: joint venture", target: "49: distribution", fill: "#36454f"},
{source: "49: distribution", target: "49: Novogynes ", fill: "#36454f"},
{source: "49: Novogynes ", target: "49: VivelleDot ", fill: "#36454f"},
{source: "49: VivelleDot ", target: "49: Novogynes ", fill: "#36454f"},
{source: "49: Novogynes ", target: "49: trade customers", fill: "#36454f"},
{source: "49: of the Novogyne ", target: "102: agreements", fill: "#da1d81"},
{source: "102: agreements", target: "102: adequately", fill: "#da1d81"},
{source: "102: adequately", target: "102: negatively", fill: "#da1d81"},
{source: "102: negatively", target: "102: operations", fill: "#da1d81"},
{source: "102: agreements", target: "START_HERE", fill: "#da1d81"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Human Resource and Employment Services</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Accuse</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Balance_sheet">Balance sheet</a></td>
      <td>In financial accounting, a balance sheet (also known as statement of financial position or statement of financial condition) is a summary of the financial balances of an individual or organization, whether it be a sole proprietorship, a business partnership, a corporation, private limited company or other organization such as government or not-for-profit entity. Assets, liabilities and ownership equity are listed as of a specific date, such as the end of its financial year.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_statement">Financial statement</a></td>
      <td>Financial statements (or financial reports) are formal records of the financial activities and position of a business, person, or other entity.\nRelevant financial information is presented in a structured manner and in a form which is easy to understand.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_law">Financial law</a></td>
      <td>Financial law is the law and regulation of the insurance, derivatives, commercial banking, capital markets and investment management sectors. Understanding Financial law is crucial to appreciating the creation and formation of banking and financial regulation, as well as the legal framework for finance generally.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Estradiol_(medication)">Estradiol (medication)</a></td>
      <td>Estradiol (E2) is a medication and naturally occurring steroid hormone. It is an estrogen and is used mainly in menopausal hormone therapy and to treat low sex hormone levels in women.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States">United States</a></td>
      <td>The United States of America (U.S.A. or USA), commonly known as the United States (U.S. or US) or America, is a country primarily located in North America. It consists of 50 states, a federal district, five major unincorporated territories, 326 Indian reservations, and nine minor outlying islands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_accounting">Financial accounting</a></td>
      <td>Financial accounting is the field of accounting concerned with the summary, analysis and reporting of financial transactions related to a business. This involves the preparation of financial statements available for public use.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Futures_contract">Futures contract</a></td>
      <td>In finance, a futures contract (sometimes called a futures) is a standardized legal contract to buy or sell something at a predetermined price for delivery at a specified time in the future, between parties not yet known to each other. The asset transacted is usually a commodity or financial instrument.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/International_Financial_Reporting_Standards">International Financial Reporting Standards</a></td>
      <td>International Financial Reporting Standards, commonly called IFRS, are accounting standards issued by the IFRS Foundation and the International Accounting Standards Board (IASB). They constitute a standardised way of describing the company's financial performance and position so that company financial statements are understandable and comparable across international boundaries.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_services">Financial services</a></td>
      <td>Financial services are the economic services provided by  the finance industry, which encompasses a broad range of businesses that manage money, including credit unions, banks, credit-card companies, insurance companies, accountancy companies, consumer-finance companies, stock brokerages, investment funds, individual asset managers, and some government-sponsored enterprises.\n\n\n== History ==\n\nThe term "financial services" became more prevalent in the United States partly as a result of the Gramm–Leach–Bliley Act of the late 1990s, which enabled different types of companies operating in the U.S. financial services industry at that time to merge.Companies usually have two distinct approaches to this new type of business.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Reliance_Retail">Reliance Retail</a></td>
      <td>Reliance Retail is an Indian retail company and a subsidiary of Reliance Industries Limited. Founded in 2006, it is the largest retailer in India in terms of revenue.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/TRIPS_Agreement">TRIPS Agreement</a></td>
      <td>The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) is an international legal agreement between all the member nations of the World Trade Organization (WTO). It establishes minimum standards for the regulation by national governments of different forms of intellectual property (IP) as applied to nationals of other WTO member nations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenuptial_agreement">Prenuptial agreement</a></td>
      <td>A prenuptial agreement, antenuptial agreement, or premarital agreement (commonly referred to as a prenup), is a written contract entered into by a couple prior to marriage or a civil union that enables them to select and control many of the legal rights they acquire upon marrying, and what happens when their marriage eventually ends by death or divorce. Couples enter into a written prenuptial agreement to supersede many of the default marital laws that would otherwise apply in the event of divorce, such as the laws that govern the division of property, retirement benefits, savings, and the right to seek alimony (spousal support) with agreed-upon terms that provide certainty and clarify their marital rights.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Joint_venture">Joint venture</a></td>
      <td>A joint venture (JV) is a business entity created by two or more parties, generally characterized by shared ownership, shared returns and risks, and shared governance. Companies typically pursue joint ventures for one of four reasons: to access a new market, particularly emerging markets; to gain scale efficiencies by combining assets and operations; to share risk for major investments or projects; or to access skills and capabilities.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/International_joint_venture">International joint venture</a></td>
      <td>An international joint venture (IJV) occurs when two businesses based in two or more countries form a partnership. A company that wants to explore international trade without taking on the full responsibilities of cross-border business transactions has the option of forming a joint venture with a foreign partner.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/AMD–Chinese_joint_venture">AMD–Chinese joint venture</a></td>
      <td>The AMD–Chinese joint venture is the agreement between the semiconductor company Advanced Micro Devices (AMD) and China-based partners to license and build x86-compatible CPUs for the Chinese-based market. It is an attempt to reduce the Chinese dependence on foreign technology, but was negotiated and agreed to well before the 2018 trade war between the US and China.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_Aircraft_Corporation">United Aircraft Corporation</a></td>
      <td>The PJSC United Aircraft Corporation (UAC) (Russian: Объединённая авиастроительная корпорация, tr. Obyedinyonnaya Aviastroitelnaya Korporatsiya (OAK)) is a Russian aerospace and defense corporation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Hindustan_Motors">Hindustan Motors</a></td>
      <td>Hindustan Motors is an Indian automotive manufacturer based in Kolkata, West Bengal, India. It is a part of the Birla Technical Services conglomerate.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Boeing–Embraer_joint_venture">Boeing–Embraer joint venture</a></td>
      <td>Boeing Brasil–Commercial was a proposed, but failed joint venture between Boeing and Embraer to design, build, and sell commercial airliners worldwide. The partnership was established in February 2019, after Boeing agreed to purchase an 80% stake in Embraer's commercial aircraft division.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Foton_Motor">Foton Motor</a></td>
      <td>Beiqi Foton Motor Co., Ltd. (Foton Motor or Foton, Chinese: 北汽福田汽车股份有限公司; pinyin: Běiqì Fútián Qìchē Gǔfèn Yǒuxiàn Gōngsī) is a Chinese company which designs and manufactures trucks, buses and sport utility vehicles .</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Master_service_agreement">Master service agreement</a></td>
      <td>A master service agreement, sometimes known as a framework agreement, is a contract reached between parties, in which the parties agree to most of the terms that will govern future transactions or future agreements.\nA master agreement delineates a schedule of lower-level service agreements, permitting the parties to quickly enact future transactions or agreements, negotiating only the points specific to the new transactions and relying on the provisions in the master agreement for common terms.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Dayton_Agreement">Dayton Agreement</a></td>
      <td>The General Framework Agreement for Peace in Bosnia and Herzegovina, also known as the Dayton Agreement or the Dayton Accords (Serbo-Croatian: Dejtonski mirovni sporazum / Дејтонски мировни споразум), is the peace agreement reached at Wright-Patterson Air Force Base near Dayton, Ohio, United States, on 21 November 1995, and formally signed in Paris, on 14 December 1995. These accords put an end to the three-and-a-half-year-long Bosnian War, one of the Yugoslav Wars.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/1991_Paris_Peace_Agreements">1991 Paris Peace Agreements</a></td>
      <td>The Paris Peace Agreements (Khmer: សន្ធិសញ្ញាសន្តិភាពទីក្រុងប៉ារីស ឆ្នាំ១៩៩១; French: Accords de paix de Paris), formally titled Comprehensive Cambodian Peace Agreements, were signed on October 23, 1991, and marked the official end of the Cambodian–Vietnamese War and the Third Indochina War. The agreement led to the deployment of the first post-Cold War peace keeping mission (UNTAC) and the first ever occasion in which the UN took over as the government of a state.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>NOVEN PHARMACEUTICALS INC      Item 1A <font color="blue">Risk Factors</font></td>
    </tr>
    <tr>
      <td>The following section <font color="blue">summarizes certain risk factors</font> that may cause     our results to <font color="blue">differ from</font> the “forward-looking statements” made in this     report or otherwise made by or on our behalf</td>
    </tr>
    <tr>
      <td>The risks and <font color="blue">uncertainties</font>     described below are not listed in order of priority and are not the only     ones we face</td>
    </tr>
    <tr>
      <td>If any of the <font color="blue">following risks actually</font> occurs, our business,     <font color="blue">financial condition</font> and results of <font color="blue"><font color="blue">operations</font> would suffer</font></td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>risks     not presently known to us or other factors not perceived by us to present     <font color="blue"><font color="blue">significant</font> risks</font> to our business at this time <font color="blue">also may impair</font> our business     operation</td>
    </tr>
    <tr>
      <td>We do not                                         21       _________________________________________________________________    [65]Table of <font color="blue">Contents       </font>undertake to update any of these forward-looking statements or to announce     the results of any revisions to these forward-looking statements except as     required by law</td>
    </tr>
    <tr>
      <td><font color="blue">Publication </font>of negative results of studies or <font color="blue">clinical trials</font> may <font color="blue">adversely</font>     impact our products</td>
    </tr>
    <tr>
      <td>From time to time, studies or <font color="blue"><font color="blue">clinical trials</font> on various aspects</font> of     <font color="blue"><font color="blue">pharmaceutical</font> products</font> are <font color="blue">conducted by academics</font> or others, including     <font color="blue"><font color="blue">government</font> agencies</font>, the results of which, when published, may have dramatic     <font color="blue">effects on</font> the markets for the <font color="blue"><font color="blue">pharmaceutical</font> products</font> that are the subject     of the study and on other similar or related <font color="blue"><font color="blue">pharmaceutical</font> products</font></td>
    </tr>
    <tr>
      <td>The     <font color="blue">publication</font> of negative results of studies or <font color="blue">clinical trials</font> related to our     products  or the <font color="blue">therapeutic areas</font> in which our <font color="blue">products compete could</font>     <font color="blue">adversely</font> affect our sales, the <font color="blue">prescription trends</font> for our products and the     reputation  of our products and <font color="blue">could also</font> cause us to be a target for     <font color="blue">product <font color="blue">liability</font></font> or other lawsuits</td>
    </tr>
    <tr>
      <td>Currently, our liquidity, results of <font color="blue">operations</font> and business prospects     are  almost  entirely  <font color="blue">dependent</font>  on sales, license royalties and fees     <font color="blue">associated with transdermal</font> HT products</td>
    </tr>
    <tr>
      <td>The market for HT products has been     <font color="blue"><font color="blue"><font color="blue">negatively</font> affected</font> by</font> the WHI study and other studies that have found that     the <font color="blue">overall health risks from</font> the use of certain HT <font color="blue">products exceed</font> the     <font color="blue">benefits from</font> the use of those <font color="blue">products among healthy postmenopausal women</font></td>
    </tr>
    <tr>
      <td>For example, total prescriptions dispensed in the HT market in the United     States  declined  by  53prca from the <font color="blue">second quarter</font> of 2002 (the quarter     <font color="blue">immediately preceding</font> the WHI study) to the <font color="blue">fourth quarter</font> of 2005</td>
    </tr>
    <tr>
      <td>In     addition, a <font color="blue">private foundation</font> has commenced a five-year study aimed at     determining whether ET use by women aged 40 to 55 reduces the risks of heart     disease</td>
    </tr>
    <tr>
      <td>The <font color="blue">study also seeks</font> to determine if <font color="blue">transdermal estrogen patches</font>     are more or <font color="blue">less beneficial than</font> an oral HT product</td>
    </tr>
    <tr>
      <td>The market for HT     products, including ours, both in the <font color="blue">United States </font>and abroad, could be     further <font color="blue">adversely</font> impacted if this <font color="blue">or <font color="blue">other HT </font></font><font color="blue">studies find</font> unacceptable     risks from HT use</td>
    </tr>
    <tr>
      <td>Any <font color="blue">further adverse</font> change in the market for HT products     could have a material <font color="blue">adverse impact on</font> our business, <font color="blue">financial position</font> and     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The FDA’s analysis of <font color="blue">potential safety issues associated with certain</font>     <font color="blue"><font color="blue">patch product</font>s</font>, including Duragesic^^® and Ortho Evra^^®, and the resulting     <font color="blue">media coverage</font> of these issues, may <font color="blue">adversely</font> affect the public’s and the     medical community’s perceptions of other <font color="blue">transdermal products</font>, including our     products, and <font color="blue">could ultimately impair</font> the <font color="blue">commercial <font color="blue">acceptance</font></font> of our     current and future <font color="blue"><font color="blue">patch product</font>s</font></td>
    </tr>
    <tr>
      <td>A 2005 study by researchers at the <font color="blue">MD Anderson Cancer Center </font>found     adverse   <font color="blue">chromosomal</font>   effects  on  12  children  treated  with  oral     <font color="blue">methylphenidate</font></td>
    </tr>
    <tr>
      <td>The FDA has announced that the <font color="blue">National Institutes </font>of     Health (NIH) and Duke University have or will undertake <font color="blue"><font color="blue">additional</font> studies</font>     designed  to  examine the <font color="blue">chromosomal</font> effects of oral <font color="blue">methylphenidate</font></td>
    </tr>
    <tr>
      <td>Additionally, as part of an ongoing FDA <font color="blue">inquiry into</font> the possible side     effects  of  ADHD <font color="blue">medications</font>, the FDA Drug Safety and Risk Management     Advisory Committee met on <font color="blue">February </font>9, 2006 to discuss the <font color="blue">cardiovascular</font>     risks  associated  with  ADHD products and recommended to the FDA that     stimulant-based ADHD <font color="blue">medications</font> carry a “black-box” warning about possible     <font color="blue">cardiac events</font></td>
    </tr>
    <tr>
      <td>Other related <font color="blue">FDA Advisory Committee </font>meetings are scheduled</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> what effect these events, as well as any other studies or     FDA actions that may occur as a result of the <font color="blue">ongoing public debate</font> in the     <font color="blue">United States </font>regarding the <font color="blue">appropriateness</font> of using <font color="blue">methylphenidate</font> and     other <font color="blue">medications</font> to <font color="blue">treat children with</font> ADHD, will have on our partner’s     ability to <font color="blue"><font color="blue">successfully</font> <font color="blue">commercialize</font></font> Daytrana^™</td>
    </tr>
    <tr>
      <td>22       _________________________________________________________________    [66]Table of <font color="blue">Contents       </font>If we cannot develop, license or acquire <font color="blue">new products</font> and <font color="blue"><font color="blue">commercialize</font> them</font>     on a <font color="blue">timely basis</font> our <font color="blue">financial position</font> and results of <font color="blue">operations</font> could be     <font color="blue">adversely</font> affected and the price of our <font color="blue"><font color="blue">common stock</font> could decline</font></td>
    </tr>
    <tr>
      <td>Our long-term strategy is <font color="blue">dependent</font> upon the <font color="blue">successful <font color="blue">development</font></font> of     new  products  and their <font color="blue">successful <font color="blue">commercialization</font></font></td>
    </tr>
    <tr>
      <td>There can be no     assurance that we will be able to identify <font color="blue">commercially promising products</font>     or  <font color="blue">technologies</font>  or  <font color="blue"><font color="blue">additional</font> indications</font> to which our products and     <font color="blue">technologies</font> may be <font color="blue">beneficially applied</font></td>
    </tr>
    <tr>
      <td>The length of time <font color="blue">necessary</font> to     complete <font color="blue">clinical trials</font> and obtain <font color="blue"><font color="blue">marketing approval</font> from <font color="blue">regulatory</font></font>     <font color="blue"><font color="blue">authorities</font> may</font> be considerable</td>
    </tr>
    <tr>
      <td>No assurance can be given that we will have     the financial resources <font color="blue">necessary</font> to complete products under <font color="blue">development</font>,     that those projects to which we <font color="blue">dedicate resources will</font> be <font color="blue">successfully</font>     completed, that we will be able to obtain <font color="blue"><font color="blue">regulatory</font> approval</font> for any such     product,  or  that  any <font color="blue">approved product</font> can be produced in commercial     quantities, at reasonable costs, and be <font color="blue">successfully</font> marketed, either by us     or by a <font color="blue">licensing partner</font></td>
    </tr>
    <tr>
      <td>A project can fail or be <font color="blue">delayed at</font> any stage of     <font color="blue">development</font>, even if <font color="blue">each prior stage</font> was completed <font color="blue">successfully</font>, which     <font color="blue">could jeopardize</font> our ability to recover our <font color="blue">investment</font> in the product</td>
    </tr>
    <tr>
      <td><font color="blue">Some     </font>of  our  <font color="blue">development</font> projects will not be completed <font color="blue">successfully</font> or on     schedule</td>
    </tr>
    <tr>
      <td>Many of the <font color="blue">factors which may</font> cause a product in <font color="blue">development</font> to     fail or be delayed, such as <font color="blue">difficult</font>y in <font color="blue">enrolling patients</font> in clinical     trials, the failure of <font color="blue">clinical trials</font>, lack of <font color="blue">sufficient supplies</font> or raw     materials,  <font color="blue">inability</font> to supply the subject product or <font color="blue"><font color="blue">technology</font> on</font> a     <font color="blue"><font color="blue">commercial scale</font> on</font> an <font color="blue">economical basis</font> and changes in <font color="blue">regulations</font>, are     beyond our control</td>
    </tr>
    <tr>
      <td>From time to time we may need to acquire licenses to patents and other     <font color="blue">intellectual</font>  property  of  third  parties to develop, <font color="blue">manufacture</font> and     <font color="blue">commercialize</font> our products</td>
    </tr>
    <tr>
      <td>There can be no assurance that we will be able     to acquire <font color="blue">such licenses on <font color="blue">commercially reasonable terms</font></font></td>
    </tr>
    <tr>
      <td>The failure to     obtain  such a <font color="blue">license could <font color="blue">negatively</font> affect</font> our ability to develop,     <font color="blue">manufacture</font> and <font color="blue">commercialize</font> certain products</td>
    </tr>
    <tr>
      <td>In some cases, we have begun     and, in the future, may begin developing a <font color="blue">product with</font> the <font color="blue">expectation</font> that     a <font color="blue">licensee will</font> be identified to assist in completing <font color="blue">development</font> and/or     marketing</td>
    </tr>
    <tr>
      <td>There can be no assurance that we will attract a business partner     for any <font color="blue">particular product</font> or will be able to negotiate an <font color="blue"><font color="blue">agreement</font> on</font>     <font color="blue">commercially reasonable terms</font></td>
    </tr>
    <tr>
      <td>If an <font color="blue">agreement</font> is not reached, our initial     <font color="blue">development</font> <font color="blue">investment</font> in any <font color="blue">such <font color="blue">product may</font></font> not be recovered</td>
    </tr>
    <tr>
      <td>If we undertake an <font color="blue">acquisition</font> of <font color="blue">technology</font>, we will incur a variety of     costs, and we may never realize the anticipated benefits of the <font color="blue">acquisition</font></td>
    </tr>
    <tr>
      <td>One of our current growth strategies is to expand our <font color="blue">technological</font>     base, including through the <font color="blue">acquisition</font> of new transdermal <font color="blue">technologies</font> that     allow for the delivery of <font color="blue"><font color="blue">additional</font> molecules through</font> the skin</td>
    </tr>
    <tr>
      <td>We may seek     to expand our <font color="blue">technological</font> base through the <font color="blue">acquisition</font> of other companies     or through the license or purchase of rights to these <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>If we     undertake an <font color="blue">acquisition</font>, the process of integrating the acquired business,     <font color="blue">technology</font> or <font color="blue">product may</font> result in unforeseen operating <font color="blue"><font color="blue">difficult</font>ies</font> and     <font color="blue"><font color="blue">expenditure</font>s</font>  and <font color="blue">may divert <font color="blue">significant</font> <font color="blue">management</font> attention from</font> our     ongoing  business  <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Moreover,  we  may fail to realize the     anticipated benefits of any <font color="blue">acquisition</font> for a variety of reasons, such as an     acquired <font color="blue">technology</font> proving to not be safe or <font color="blue">effective</font> in <font color="blue">later clinical</font>     trials or if the <font color="blue">technology</font> is <font color="blue">later found</font> to <font color="blue">infringe upon</font> the <font color="blue">intellectual</font>     <font color="blue">property rights</font> of another</td>
    </tr>
    <tr>
      <td>It is possible that we may fund any future     <font color="blue">acquisition</font> by issuing equity or debt securities, <font color="blue">which could</font> dilute the     <font color="blue">ownership percentage</font> of <font color="blue">current <font color="blue">stockholders</font></font> or limit our financial or     operating <font color="blue">flexibility as</font> a result of <font color="blue">restrictive covenants</font> related to new     debt</td>
    </tr>
    <tr>
      <td><font color="blue">Acquisition </font>efforts can <font color="blue">consume <font color="blue">significant</font> <font color="blue">management</font> attention</font> and     require  substantial  <font color="blue"><font color="blue">expenditure</font>s</font>, <font color="blue">which could</font> detract from our other     programs</td>
    </tr>
    <tr>
      <td>In  addition, we may devote time and resources to potential     <font color="blue">acquisition</font>s that are never completed</td>
    </tr>
    <tr>
      <td>23       _________________________________________________________________    [67]Table of <font color="blue">Contents       </font>We <font color="blue"><font color="blue">depend on</font> partners</font> to obtain <font color="blue"><font color="blue">regulatory</font> approval</font> for, and to market and     sell, certain of our products</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">marketing partners</font> sell products</font> that     <font color="blue">compete with</font> our products</td>
    </tr>
    <tr>
      <td>We depend upon collaborative <font color="blue">agreement</font>s with other <font color="blue">pharmaceutical</font>     companies to obtain <font color="blue"><font color="blue">regulatory</font> approval</font> for and to market and <font color="blue">sell certain</font>     of our products</td>
    </tr>
    <tr>
      <td>To <font color="blue">help alleviate</font> the up-front financial burden of seeking     <font color="blue">product approval</font> and <font color="blue"><font color="blue">commercializing</font> products</font> we <font color="blue">often seek out strategic</font>     partners  to  whom we can license our products</td>
    </tr>
    <tr>
      <td>Under the terms of the     Novogyne <font color="blue">joint venture</font>, Novartis is responsible for the <font color="blue">distribution</font> of     Novogyne’s products, including Vivelle-Dot^™, and for selling Novogyne’s     products  to  its <font color="blue">trade customers</font></td>
    </tr>
    <tr>
      <td>For Daytrana^™, we have granted the     <font color="blue">exclusive marketing rights</font> to Shire and we are working jointly with Shire to     obtain FDA approval of our <font color="blue">methylphenidate</font> patch</td>
    </tr>
    <tr>
      <td>Failure of Novartis, Shire     and our other partners to <font color="blue">adequately</font> support our products would cause the     quantity of products purchased from us and the amount of fees and royalties     <font color="blue">ultimately paid</font> to us to be reduced and <font color="blue">would therefore</font> have a material     adverse  effect  on our business and <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">partners may</font> have     <font color="blue">different</font>  and, sometimes, competing priorities from ours</td>
    </tr>
    <tr>
      <td>Some of our     partners, including Novartis and Shire, market and <font color="blue">sell products <font color="blue">competitive</font></font>     with  ours</td>
    </tr>
    <tr>
      <td>Shire has a portfolio of ADHD products and has licensed an     <font color="blue"><font color="blue">amphetamine</font> pro drug</font> for the treatment of ADHD for which an NDA was filed in     <font color="blue">December </font>2005</td>
    </tr>
    <tr>
      <td>The  marketing  <font color="blue">organizations</font>  of  our <font color="blue">partners may</font> be     <font color="blue">unsuccessful</font>, or those <font color="blue">partners may</font> assign a <font color="blue">lower level</font> of priority to the     marketing of our products</td>
    </tr>
    <tr>
      <td>If one or more <font color="blue">partners fails</font> to pursue the     marketing  of our products as planned, or if marketing of any of those     products is <font color="blue">otherwise delayed</font>, our business, <font color="blue">financial position</font> and results     of <font color="blue">operations</font> may be <font color="blue"><font color="blue">negatively</font> affected</font></td>
    </tr>
    <tr>
      <td>Absent these <font color="blue">marketing partners</font>,     we do not presently have a <font color="blue"><font color="blue">significant</font> direct marketing channel</font> to health     <font color="blue">care providers</font> for our drug delivery <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>We  do  not  control Novogyne and we may face <font color="blue">additional</font> risks because     Novartis, our <font color="blue">joint venture</font> partner, has <font color="blue"><font color="blue">significant</font>ly greater resources</font>     than we do</td>
    </tr>
    <tr>
      <td>Our equity in earnings <font color="blue">of Novogyne </font><font color="blue">contributed <font color="blue">substantially</font></font> all of our     income before <font color="blue">income taxes</font> in 2005, and Novogyne’s results <font color="blue">will likely</font>     continue to be material to us in the future</td>
    </tr>
    <tr>
      <td>Because, among other things, we     are vastly <font color="blue">different</font> in size from Novartis, and because Novartis and its     <font color="blue">affiliates</font> sell competing products outside of Novogyne, our <font color="blue">interests may</font>     not  always be aligned</td>
    </tr>
    <tr>
      <td>This may result in <font color="blue">potential conflicts between</font>     Novartis and us on matters relating to Novogyne which we may not be able to     <font color="blue">resolve on</font> favorable terms or at all</td>
    </tr>
    <tr>
      <td><font color="blue">Under the Novogyne </font><font color="blue">joint venture</font>     <font color="blue">agreement</font>,  <font color="blue">Novartis  </font>has the right to dissolve Novogyne <font color="blue">under certain</font>     <font color="blue">circumstances</font></td>
    </tr>
    <tr>
      <td>Novogyne’s Management Committee is comprised of a majority of     <font color="blue">representatives from</font> Novartis</td>
    </tr>
    <tr>
      <td>While <font color="blue">certain <font color="blue">significant</font> corporate actions</font>     require the <font color="blue">supermajority vote</font> of the <font color="blue">committee members</font>, we do not control     Novogyne</td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">joint venture</font> operating <font color="blue">agreement</font> has a buy/sell     provision that either <font color="blue">Noven or Novartis </font><font color="blue">may trigger by notifying</font> the other     party of the <font color="blue">price at which</font> the <font color="blue">triggering party would</font> be willing to acquire     the other party’s entire interest in the <font color="blue">joint venture</font></td>
    </tr>
    <tr>
      <td>Novartis is a larger     <font color="blue"><font color="blue">company with</font> greater financial resources</font>, and therefore may be in a better     position to be the purchaser if the provision is triggered</td>
    </tr>
    <tr>
      <td>If the provision     is triggered <font color="blue">and Novartis </font>is the purchaser, there can be no assurance that     we would be able to reinvest the proceeds of the sale in a manner that would     result in <font color="blue">sufficient earnings</font> to offset the loss of <font color="blue">earnings from</font> Novogyne</td>
    </tr>
    <tr>
      <td>If the provision is triggered and we are the purchaser, there can be no     assurance that we would not be <font color="blue">adversely</font> affected by the changes in capital     and/or debt structure that likely would be required to finance the purchase     <font color="blue">transaction</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on</font> Novartis to perform all financial, <font color="blue">accounting</font>, <font color="blue">regulatory</font>,     compliance, inventory, sales <font color="blue">deductions</font> and other functions for Novogyne</td>
    </tr>
    <tr>
      <td><font color="blue">Under the Novogyne </font><font color="blue">joint venture</font>, Novartis is responsible for providing     Novogyne with all financial, <font color="blue">accounting</font>, legal and <font color="blue">regulatory</font> services,     including <font color="blue">monitoring inventory levels</font> and                                         24       _________________________________________________________________    [68]Table of <font color="blue">Contents       </font>estimating and <font color="blue">recording sales <font color="blue">allowances</font></font> and returns <font color="blue">for Novogyne </font>(which     include  reserves  and  <font color="blue">allowances</font> related to <font color="blue">product returns</font>), and is     <font color="blue">primarily responsible</font> for ensuring compliance with applicable <font color="blue">regulations</font>     relating to sales and <font color="blue">marketing activities</font></td>
    </tr>
    <tr>
      <td>Novartis is responsible for <font color="blue">internal controls</font> over financial reporting     for Novogyne, so our ability to assess their <font color="blue">effective</font>ness at maintaining     those <font color="blue">internal controls</font> is <font color="blue">necessarily</font> limited</td>
    </tr>
    <tr>
      <td>Failure by Novartis to     perform its <font color="blue">obligations</font> under the <font color="blue">joint venture</font> could <font color="blue">negatively</font> affect the     <font color="blue">financial position</font> and results of <font color="blue">operations</font> <font color="blue">of Novogyne </font>and us</td>
    </tr>
    <tr>
      <td><font color="blue">Because Novartis </font>maintains the <font color="blue">relevant data</font>, we may have limited     ability to <font color="blue">accurately forecast</font> the amount of sales <font color="blue">allowances</font> in any period</td>
    </tr>
    <tr>
      <td><font color="blue">If Novartis </font><font color="blue">materially</font> changes the <font color="blue">assumptions</font> it uses in determining the     reserve, Novogyne may be required to record an <font color="blue">additional</font> reserve allowance     on  its  <font color="blue">financial statements</font>, <font color="blue">which would</font> <font color="blue">adversely</font> affect Novogyne’s     operating results during the period in which the <font color="blue">determination</font> or reserve     were made, and would, <font color="blue">consequently</font> also reduce our <font color="blue">earnings attributable</font> to     our <font color="blue">investment</font> in Novogyne for that period</td>
    </tr>
    <tr>
      <td>More <font color="blue">generally</font>, any material     errors by Novartis in performing its <font color="blue">accounting</font> functions <font color="blue">for Novogyne </font>could     lead to a <font color="blue">subsequent restatement</font> of Novogyne’s <font color="blue">financial statements</font> and in     turn require us to restate our <font color="blue">financial statements</font> as well</td>
    </tr>
    <tr>
      <td>We  may  be  unable to obtain <font color="blue">marketing approval</font> for our <font color="blue">new products</font>,     including Daytrana^™, on a <font color="blue">timely basis</font> or at all</td>
    </tr>
    <tr>
      <td>We  are  not  able to market our products (including <font color="blue">generic drug</font>     products)  in  the  <font color="blue">United States </font>or other <font color="blue">jurisdictions without first</font>     obtaining <font color="blue">marketing approval</font> from the FDA or an <font color="blue">equivalent foreign agency</font></td>
    </tr>
    <tr>
      <td>The process of obtaining FDA approval for a new <font color="blue">product may</font> take several     years and is likely to involve the <font color="blue"><font color="blue">expenditure</font>s</font> of substantial resources</td>
    </tr>
    <tr>
      <td>The process is subject to the <font color="blue">broad authority</font> and <font color="blue">discretion</font> of the FDA In     September 2005, the FDA <font color="blue">advised us</font> that it did not expect to approve our     ANDA for our <font color="blue">fentanyl patch</font> and was <font color="blue">consequently</font> ceasing its review of our     ANDA, <font color="blue">based on</font> the FDA’s <font color="blue">assessment</font> of <font color="blue">potential safety concerns</font> related to     the <font color="blue">higher drug content</font> in our <font color="blue"><font color="blue">generic product</font> versus</font> the <font color="blue">branded product</font></td>
    </tr>
    <tr>
      <td>Due to the FDA’s <font color="blue">determination</font>, Noven and Endo agreed in <font color="blue">December </font>2005 to     terminate the fentanyl portion of the 2004 license <font color="blue">agreement</font> as well as the     fentanyl supply <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>Noven is <font color="blue">currently evaluating</font> the <font color="blue">feasibility</font> of     <font color="blue">reformulating</font> the <font color="blue">fentanyl patch</font> to address the FDA’s concerns</td>
    </tr>
    <tr>
      <td>In <font color="blue">December </font>2005, we received an <font color="blue">approvable letter from</font> the FDA for     Daytrana^™</td>
    </tr>
    <tr>
      <td>The <font color="blue">approvable letter contains proposed revisions</font> to labeling,     <font color="blue">as well as requests</font> for data clarification, post-marketing surveillance, and     post-marketing  studies</td>
    </tr>
    <tr>
      <td>We  cannot  assure  that  the results of any     post-marketing studies will be favorable or that the FDA will not take     actions that will limit the <font color="blue">marketability</font> of Daytrana^™ as a result of these     studies</td>
    </tr>
    <tr>
      <td>We <font color="blue">also cannot</font> be certain that the labeling that is ultimately     approved for Daytrana^™ will not restrict or otherwise <font color="blue">adversely</font> impact the     <font color="blue">marketability</font> of the product</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> that we will obtain the <font color="blue">necessary</font> <font color="blue"><font color="blue">regulatory</font> approval</font>     for our products under <font color="blue">development</font> or that any <font color="blue">such <font color="blue">approval will</font></font> be free     <font color="blue">from unduly burdensome <font color="blue">conditions</font></font> or <font color="blue">limitations</font></td>
    </tr>
    <tr>
      <td>In light of the WHI and     <font color="blue">other HT </font>studies, it is possible that <font color="blue">healthcare regulators could delay</font> the     approval of HT products as well as hormonal therapies for HSDD or require     that any such <font color="blue">new products</font> be subject to more extensive or more rigorous     study and testing prior to being approved, or could receive approval subject     to more extensive <font color="blue">conditions</font> or <font color="blue">limitations</font></td>
    </tr>
    <tr>
      <td>25       _________________________________________________________________    [69]Table of <font color="blue">Contents       </font>     As a result of the <font color="blue">publicity surrounding</font> COX-2 inhibitors, certain     <font color="blue">antidepressants</font>, and the <font color="blue">publicity surrounding</font> HT products, both citizen’s     groups  and  interests  in  the <font color="blue">United States </font>Congress have called for     <font color="blue">investigation</font> and <font color="blue">possible reform</font> of the FDA <font color="blue">approval process</font></td>
    </tr>
    <tr>
      <td>In response     to these concerns, during 2005, the FDA created an in<font color="blue">dependent</font> Drug Safety     Oversight Board comprised of FDA representatives, medical experts and other     <font color="blue">third parties</font> to oversee the <font color="blue">management</font> of <font color="blue">drug safety issues</font>, and the FDA     may impose more <font color="blue">stringent standards</font> in approving or monitoring <font color="blue">new products</font>     compared to the <font color="blue">standards applied</font> in the past</td>
    </tr>
    <tr>
      <td>We believe these changes will     make drug <font color="blue">development</font> more lengthy, risky and expensive</td>
    </tr>
    <tr>
      <td>Due to the <font color="blue">diversity</font> of <font color="blue">proposals put forth</font>, we <font color="blue">cannot predict</font> what     effect future changes in <font color="blue">regulations</font> or <font color="blue">legal interpretations</font>, if, when and     <font color="blue">as ultimately promulgated may</font> have on our business</td>
    </tr>
    <tr>
      <td>Our  approved  products  may  not achieve the expected level of market     <font color="blue">acceptance</font></td>
    </tr>
    <tr>
      <td>Even if we are able to obtain <font color="blue"><font color="blue">regulatory</font> approval</font> for our <font color="blue">new products</font>,     our success will <font color="blue">depend on</font> their market <font color="blue">acceptance</font></td>
    </tr>
    <tr>
      <td><font color="blue">Substantially </font>all of our     revenues are <font color="blue">generated through sales</font> of transdermal <font color="blue">delivery systems</font>, which     <font color="blue">generally</font> are more <font color="blue"><font color="blue">expensive than</font> oral formations</font></td>
    </tr>
    <tr>
      <td>Our products are marketed     primarily  to  physicians,  some  of whom are reluctant to prescribe a     transdermal  delivery  system  when  an <font color="blue"><font color="blue">alternative</font> delivery system</font> is     available</td>
    </tr>
    <tr>
      <td>We and our licensees must <font color="blue">demonstrate</font> to prescribing physicians     the benefits of transdermal delivery, <font color="blue">especially</font> <font color="blue">with respect</font> to products     such  as  our  <font color="blue">methylphenidate</font>  patch  for which there is presently no     transdermal system on the market</td>
    </tr>
    <tr>
      <td>The <font color="blue">commercial success</font> of our products is     also based in part <font color="blue">on patient preference</font>, and <font color="blue"><font color="blue">difficult</font>ies</font> in obtaining     patient <font color="blue">acceptance</font> of our <font color="blue">transdermal <font color="blue">delivery systems</font> may similarly impact</font>     our ability to market our products</td>
    </tr>
    <tr>
      <td>Even if we obtain FDA approval for Daytrana^™, the market for this     <font color="blue">product may</font> be <font color="blue"><font color="blue"><font color="blue">negatively</font> affected</font> by</font> the outcome of the FDA’s ongoing     <font color="blue">inquiry into</font> the possible side effects of ADHD <font color="blue">medications</font>, the FDA Drug     Safety and Risk Management Advisory Committee’s <font color="blue">recent recommendation</font> that     ADHD <font color="blue">medications</font> carry a “black-box” warning about possible <font color="blue">cardiac events</font>,     a 2005 study by researchers at the <font color="blue">MD Anderson Cancer Center </font>that found     adverse   <font color="blue">chromosomal</font>   effects  on  12  children  treated  with  oral     <font color="blue">methylphenidate</font>, as well as <font color="blue">ongoing public debate</font> in the <font color="blue">United States </font>    regarding the <font color="blue">appropriateness</font> of using <font color="blue">methylphenidate</font> and other <font color="blue">medications</font>     to <font color="blue">treat children with</font> ADHD We expect that this <font color="blue">debate will continue</font> for     the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>The outcome of this debate is uncertain, and we     <font color="blue">cannot predict</font> what impact, if any, the <font color="blue">increased public attention will</font> have     on the market for <font color="blue">products indicated</font> for ADHD or on our <font color="blue">methylphenidate</font>     patch</td>
    </tr>
    <tr>
      <td>Because at least part of the stigma results from the fact that most     of   the  current  products  are  <font color="blue"><font color="blue">Schedule II </font> </font>controlled  substances,     non-<font color="blue">Schedule II </font><font color="blue"><font color="blue">products may</font> benefit from</font> this <font color="blue">controversy at</font> the expense of     the  <font color="blue">methylphenidate</font> and <font color="blue">amphetamine</font>-based products on the market</td>
    </tr>
    <tr>
      <td>”     Failure to comply with our supply <font color="blue">agreement</font>s or otherwise <font color="blue">adequately</font> supply     our products to our licensees could <font color="blue">negatively</font> affect our <font color="blue">financial position</font>     and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our supply <font color="blue">agreement</font>s with our licensees impose strict <font color="blue">obligations</font> on     <font color="blue">us <font color="blue">with respect</font></font> to the <font color="blue">manufacture</font> and supply of our products</td>
    </tr>
    <tr>
      <td>Failure to     comply with the terms of these supply <font color="blue">agreement</font>s may result in our being     unable to supply product to our licensees, resulting in lost revenues by us     and  potential  <font color="blue">responsibility</font>  for damages and losses suffered by our     licensees</td>
    </tr>
    <tr>
      <td>Our  supply <font color="blue">agreement</font> for Vivelle^^® and Vivelle-Dot^™ has     expired</td>
    </tr>
    <tr>
      <td>Since the expiration of that supply <font color="blue">agreement</font>, the parties have     continued to operate in <font color="blue">accordance</font> with the supply <font color="blue">agreement</font>’s                                         26       _________________________________________________________________    [70]Table of <font color="blue">Contents       </font><font color="blue">commercial terms</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> that we <font color="blue">will enter into</font> a new supply     <font color="blue">agreement</font>  on  satisfactory  terms or at all</td>
    </tr>
    <tr>
      <td>It is not clear that the     non-<font color="blue">commercial terms</font> of the supply <font color="blue">agreement</font> would be <font color="blue">enforceable with</font>     respect to post-expiration events or <font color="blue">occurrences</font></td>
    </tr>
    <tr>
      <td>Due to our dependence on     Novogyne, we may be unable to negotiate favorable business <font color="blue">terms with them</font>     or resolve any dispute that we may be involved in with them in a favorable     manner</td>
    </tr>
    <tr>
      <td><font color="blue">Failure  </font>to  continue operating in <font color="blue">accordance</font> with the supply     <font color="blue">agreement</font>’s <font color="blue">commercial terms</font> could have a material adverse effect on our     business, results of <font color="blue">operations</font> and <font color="blue">financial position</font></td>
    </tr>
    <tr>
      <td><font color="blue">Designation </font>of a new     supplier  and  approval  of  a  new supply <font color="blue">agreement</font> would require the     <font color="blue">affirmative</font>  vote of four of the <font color="blue">five members</font> of Novogyne’s Management     Committee</td>
    </tr>
    <tr>
      <td>Accordingly, both <font color="blue">Novartis and Noven </font><font color="blue">must agree on</font> Novogyne’s     supplier</td>
    </tr>
    <tr>
      <td>Our <font color="blue">products may</font> be recalled</td>
    </tr>
    <tr>
      <td><font color="blue">Product  </font>recalls  or product field alerts may be <font color="blue">initiated at</font> the     <font color="blue">discretion</font> of Noven (if we have <font color="blue">regulatory</font> authority for the product), our     partners (if they have <font color="blue">regulatory</font> authority for the product), the FDA, other     <font color="blue"><font color="blue">government</font> agencies</font>, or a <font color="blue">combination</font> of these parties</td>
    </tr>
    <tr>
      <td>Our <font color="blue">products may</font> be     recalled  for <font color="blue">various reasons</font> including the failure of our products to     maintain their <font color="blue">stability through</font> their expiration dates, <font color="blue">manufacturing</font>     issues, quality claims, safety issues, disputed labeling claims or other     reasons</td>
    </tr>
    <tr>
      <td>We have experienced a number of <font color="blue">production issues</font>, some of which     have led to recalls in the past</td>
    </tr>
    <tr>
      <td>Among other risks, the past recalls of our     products, or any <font color="blue">further impact</font> of the issues causing these recalls, could     result in a decision to: recall all or a <font color="blue">significant</font> portion of an affected     product in <font color="blue">distribution</font> until a <font color="blue">definitive root</font> cause has been identified     and any required <font color="blue">corrective action</font> has been completed; <font color="blue">cease production</font> or     shipment of <font color="blue">new product until</font> a <font color="blue">definitive root</font> cause has been identified     and  any  required <font color="blue">corrective action</font> has been completed; or reduce the     shelf-life of the <font color="blue">affected product</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> that there will not be     recalls of our products in the future</td>
    </tr>
    <tr>
      <td>We do not carry any insurance to     cover the risk of a <font color="blue">potential product recall</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">significant</font> product recall     could <font color="blue">materially</font> affect our sales, the <font color="blue">prescription trends</font> for the products     and our reputation and the reputation of the product</td>
    </tr>
    <tr>
      <td>In these cases, our     business, results of <font color="blue">operations</font> and <font color="blue">financial condition</font> could be <font color="blue">materially</font>     and <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>Failure to comply with applicable <font color="blue">regulations</font> may result in product recalls     and/or penalties</td>
    </tr>
    <tr>
      <td>Our <font color="blue">operations</font> are subject to extensive regulation by <font color="blue">government</font>al     <font color="blue">authorities</font> in the <font color="blue">United States </font>and other <font color="blue">countries <font color="blue">with respect</font></font> to the     <font color="blue">development</font>, testing, approval, <font color="blue">manufacture</font>, labeling, marketing and sale of     <font color="blue"><font color="blue">pharmaceutical</font> products</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">regulations</font> are wide-ranging and govern,     among other things: adverse drug experience reporting, product promotion,     <font color="blue">product pricing</font> and discounting, drug sample accountability, drug product     stability, product <font color="blue">manufacturing</font>, including good <font color="blue"><font color="blue">manufacturing</font> practices</font>,     and product changes or <font color="blue">modifications</font></td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">facilities handle</font>     controlled  substances,  resulting  in <font color="blue">additional</font> extensive <font color="blue">regulatory</font>     <font color="blue">requirements</font>  and  oversight</td>
    </tr>
    <tr>
      <td><font color="blue">Compliance </font>with the extensive <font color="blue">government</font>     <font color="blue">regulations</font>  applicable  to  our  business  requires the <font color="blue">allocation</font> of     <font color="blue">significant</font> time, effort and expense</td>
    </tr>
    <tr>
      <td>Even if a product is <font color="blue">approved by</font> a     <font color="blue">regulatory</font> authority, <font color="blue">product approval</font>s may be withdrawn after the product     reaches the market if compliance with <font color="blue">regulatory</font> standards is not maintained     or  if problems occur regarding the safety or efficacy of the product</td>
    </tr>
    <tr>
      <td>Failure to comply with <font color="blue">government</font>al <font color="blue">regulations</font> may result in fines, warning     letters or other negative written observations, unanticipated compliance     <font color="blue"><font color="blue">expenditure</font>s</font>, <font color="blue">interruption</font>s or suspension of production and resulting loss     of sales, product seizures or recalls, injunctions prohibiting further     sales,  withdrawal  of <font color="blue">previously approved marketing <font color="blue">application</font>s</font>, and     criminal  <font color="blue">prosecution</font></td>
    </tr>
    <tr>
      <td>Under the terms <font color="blue">of the Novogyne </font><font color="blue">joint venture</font>,     Novartis is responsible for providing                                         27       _________________________________________________________________    [71]Table of <font color="blue">Contents       </font><font color="blue">regulatory</font> services</td>
    </tr>
    <tr>
      <td>There can be no assurance that Novartis will comply     with these <font color="blue">regulations</font> or that any <font color="blue">violation by</font> Novartis will not have an     adverse effect on us</td>
    </tr>
    <tr>
      <td>We face scale-up risks in the <font color="blue">manufacture</font> of <font color="blue">new products</font> in commercial     quantities</td>
    </tr>
    <tr>
      <td>Our <font color="blue">development</font>al <font color="blue">methylphenidate</font> patch is a new product that we have     never <font color="blue">manufacture</font>d on a <font color="blue">commercial scale</font></td>
    </tr>
    <tr>
      <td><font color="blue">Inefficiencies </font>and other scale-up     problems  may  occur  in  the process of <font color="blue">manufacturing</font> <font color="blue">new products</font> in     <font color="blue">commercial quantities</font></td>
    </tr>
    <tr>
      <td>If we do not <font color="blue">adequately</font> and timely scale-up our     <font color="blue">manufacturing</font>  processes  for  new  products  or <font color="blue">otherwise meet supply</font>     <font color="blue">requirements</font>, the success of our <font color="blue">new <font color="blue">product launch</font>es</font> and <font color="blue">revenues could</font> be     <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>It may also result in Shire or, if permitted under our     <font color="blue">agreement</font>s, our other <font color="blue">collaboration</font> partners relying more heavily on second     <font color="blue">manufacturing</font> sources, thus reducing the <font color="blue">manufacturing</font> revenues that we     would otherwise realize</td>
    </tr>
    <tr>
      <td>It <font color="blue">could also</font> jeopardize our ability to obtain     <font color="blue">milestone <font color="blue">payments under</font></font> the applicable <font color="blue">transaction</font></td>
    </tr>
    <tr>
      <td>In addition, the active     ingredient in our <font color="blue">methylphenidate</font> patch is more <font color="blue">expensive than</font> the active     <font color="blue">ingredients</font>  in  our HT <font color="blue"><font color="blue">patch product</font>s</font></td>
    </tr>
    <tr>
      <td>If we experience <font color="blue">manufacturing</font>     <font color="blue"><font color="blue">difficult</font>ies</font> such as quality problems, yield deficiencies or similar issues,     our overall <font color="blue">manufacturing</font> costs may be <font color="blue">higher than</font> anticipated</td>
    </tr>
    <tr>
      <td>We rely on a <font color="blue">single supplier</font> or a limited number of suppliers for certain     <font color="blue">raw materials</font> and <font color="blue">compounds used</font> in our products</td>
    </tr>
    <tr>
      <td>Certain <font color="blue">raw materials</font> and <font color="blue">components used</font> in the <font color="blue">manufacture</font> of our     products, including <font color="blue">essential polymer adhesives</font>, are <font color="blue">available from</font> limited     sources,  and,  in some cases, a <font color="blue">single source</font></td>
    </tr>
    <tr>
      <td>Our NDA for Daytrana^™     includes  only  <font color="blue">one supplier</font> of the active <font color="blue">pharmaceutical</font> compound</td>
    </tr>
    <tr>
      <td>In     addition, <font color="blue">regulatory</font> <font color="blue">authorities</font> must <font color="blue">generally</font> approve raw material sources     for <font color="blue">transdermal products</font>, and in the case of <font color="blue">controlled substances</font>, the DEA     <font color="blue">sets quotas</font> for <font color="blue">controlled substances</font>, including <font color="blue">methylphenidate</font>, fentanyl     and <font color="blue">amphetamine</font>, and we must receive <font color="blue">authorization from</font> the DEA to handle     these substances</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> that we will be <font color="blue">granted sufficient</font> DEA     quota  to  meet  production <font color="blue">requirements</font> for <font color="blue">controlled substances</font></td>
    </tr>
    <tr>
      <td>In     <font color="blue">December </font>2005, the DEA <font color="blue">granted us procurement quota</font> of <font color="blue">methylphenidate</font> raw     material  sufficient to <font color="blue">manufacture</font> launch supplies of Daytrana^™</td>
    </tr>
    <tr>
      <td>Our     <font color="blue">application</font> for <font color="blue">additional</font> procurement quota is <font color="blue">currently pending at</font> the     DEA We <font color="blue">cannot guarantee</font> the timing or quantity of future DEA awards of     <font color="blue">methylphenidate</font> procurement quota <font color="blue">necessary</font> for the <font color="blue">ongoing production</font> of     Daytrana^™, and the timing of any <font color="blue">future award may impact</font> the success of     <font color="blue">product launch</font> and <font color="blue">market penetration</font></td>
    </tr>
    <tr>
      <td><font color="blue">Without  </font><font color="blue">adequate approved supplies</font> of <font color="blue">raw materials</font> or packaging     supplies, our <font color="blue">manufacturing</font> <font color="blue">operations</font> could be <font color="blue">interrupted until</font> another     supplier is identified, our <font color="blue">products approved</font> and <font color="blue">trading terms with</font> this     <font color="blue">new supplier negotiated</font></td>
    </tr>
    <tr>
      <td>We may not be able to identify an <font color="blue">alternative</font>     supplier and any supplier that we do identify may not be able to obtain the     requisite <font color="blue"><font color="blue">regulatory</font> approval</font>s in a <font color="blue">timely manner</font>, or at all</td>
    </tr>
    <tr>
      <td>Furthermore,     we  may  not  be able to negotiate favorable terms with an <font color="blue">alternative</font>     supplier</td>
    </tr>
    <tr>
      <td>Any <font color="blue">disruptions</font> in our <font color="blue">manufacturing</font> <font color="blue">operations</font> from the loss of     an <font color="blue">approved supplier may</font> cause us to <font color="blue">incur increased costs</font> and <font color="blue">lose revenues</font>     and may have an adverse effect on our <font color="blue">relationships with</font> our partners and     customers, any of <font color="blue">which could</font> have adverse <font color="blue">effects on</font> our business and     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Some <font color="blue">raw materials</font> used in our products are supplied     by companies that <font color="blue">restrict certain medical uses</font> of their products</td>
    </tr>
    <tr>
      <td>While our     use is presently acceptable, there can be no assurance that <font color="blue">such companies</font>     will not expand their <font color="blue">restrictions</font> to include our <font color="blue">application</font>s</td>
    </tr>
    <tr>
      <td>Our business     also  faces the risk that <font color="blue"><font color="blue">third party</font> suppliers may supply us with raw</font>     materials that do not meet required <font color="blue">specification</font>s, which, if <font color="blue">undetected by</font>     us, could cause our products to test out of <font color="blue">specification</font> and require us to     recall the <font color="blue">affected product</font></td>
    </tr>
    <tr>
      <td>28       _________________________________________________________________    [72]Table of <font color="blue">Contents       </font>We face <font color="blue">significant</font> <font color="blue">competition</font>, which may result in <font color="blue">others discovering</font>,     developing or <font color="blue"><font color="blue">commercializing</font> products</font> before, or more <font color="blue">successfully</font>, than we     do</td>
    </tr>
    <tr>
      <td>We <font color="blue">face <font color="blue">competition</font> from</font> a number of companies in the <font color="blue">development</font> of     transdermal drug delivery products as well as products using other drug     <font color="blue">delivery systems</font>, and <font color="blue">competition</font> is expected to <font color="blue">intensify as</font> more companies     enter the field</td>
    </tr>
    <tr>
      <td>Some of these companies are <font color="blue">substantially</font> larger than we     are and have greater resources than we do, as well as greater experience in     developing and <font color="blue">commercializing</font> <font color="blue"><font color="blue">pharmaceutical</font> products</font></td>
    </tr>
    <tr>
      <td>As a result, they     may succeed before us in developing competing <font color="blue">technologies</font> or obtaining     <font color="blue">government</font>al  approvals  for products</td>
    </tr>
    <tr>
      <td>Our products <font color="blue">compete with</font> other     <font color="blue">transdermal products</font> as well as <font color="blue">alternative</font> dosage forms of the same or     comparable chemical entities, as well as non-drug therapies</td>
    </tr>
    <tr>
      <td>The ADHD market     is very <font color="blue">competitive</font> and our receipt of the sales-based milestones under the     Shire <font color="blue">agreement</font> <font color="blue">depends on</font> the <font color="blue">sales levels</font> achieved by Shire, <font color="blue">which already</font>     markets non-<font color="blue">methylphenidate</font> ADHD products</td>
    </tr>
    <tr>
      <td>Other <font color="blue"><font color="blue"><font color="blue">competitor</font>s</font> marketing</font> or     developing   ADHD   products  include  Johnson  &amp;  Johnson,  Novartis,     Glaxo-Smithkline, Bristol-Myers Squibb, Abbott Laboratories, Celltech,     Cephalon  and  Lilly</td>
    </tr>
    <tr>
      <td>Johnson  &amp;  Johnson  markets  Concerta^^®,  the     market-leading  <font color="blue">methylphenidate</font> product, <font color="blue">and Novartis </font>and Lilly market     <font color="blue">competitive</font> ADHD products</td>
    </tr>
    <tr>
      <td>Strattera^^®, a non-stimulant, non-controlled     substance therapy, has gained <font color="blue">significant</font> market share since being launched     by Lilly in 2003</td>
    </tr>
    <tr>
      <td>If Strattera^^® or other therapies in <font color="blue">development</font> by other     <font color="blue">companies become</font> recognized <font color="blue">as therapeutically</font> superior to stimulants, or     are  preferred  by physicians, parents and/or patients, the market for     Daytrana^™ would be <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>Shire has licensed an <font color="blue">amphetamine</font>     pro drug for the treatment of ADHD which, although a stimulant, may not be     designated  as  a  <font color="blue">Schedule II </font>controlled substance</td>
    </tr>
    <tr>
      <td>These <font color="blue">competitive</font>     products,  <font color="blue">especially</font>  those  already  marketed by Shire and those not     designated as <font color="blue">controlled substances</font>, may <font color="blue">negatively</font> impact Shire’s ability     to  gain  market  share  for Daytrana^™ and therefore may decrease the     likelihood that we will receive the sales-based milestone payments</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> that our <font color="blue">products will</font> compete <font color="blue">successfully</font> against     <font color="blue">competitive</font> products or that <font color="blue">development</font>s by others will not render our     products  obsolete or un<font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td>If we cannot maintain <font color="blue">competitive</font>     products and <font color="blue">technologies</font>, our current and potential strategic <font color="blue">partners may</font>     choose to adopt the drug delivery <font color="blue">technologies</font> of our <font color="blue"><font color="blue">competitor</font>s</font> or their     own <font color="blue">internally</font> developed <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>may use legal, <font color="blue">regulatory</font> and <font color="blue">legislative strategies</font> to prevent     or delay our launch of <font color="blue"><font color="blue">generic product</font>s</font></td>
    </tr>
    <tr>
      <td>The Hatch-Waxman Act provides for a period of 180 days of generic     <font color="blue">marketing exclusivity</font> for each ANDA applicant that is first to file an ANDA     containing   a   <font color="blue">certification</font>   of  <font color="blue">invalidity</font>,  non-<font color="blue">infringement</font>  or     <font color="blue">unenforceability</font> related to a <font color="blue">patent listed</font> in the FDA “Orange Book” with     respect  to a reference listed drug product, <font color="blue">commonly referred</font> to as a     <font color="blue">Paragraph IV </font><font color="blue">certification</font></td>
    </tr>
    <tr>
      <td>During this <font color="blue">exclusivity period</font>, the FDA cannot     <font color="blue">grant final approval</font> to any other <font color="blue">Paragraph IV </font>filer</td>
    </tr>
    <tr>
      <td><font color="blue">If an ANDA </font>containing     a <font color="blue">Paragraph IV </font><font color="blue">certification</font> is successful, it <font color="blue">generally</font> results in higher     market share, <font color="blue">net revenues</font> and gross margin for that applicant for a period     of time</td>
    </tr>
    <tr>
      <td>Even if we obtain FDA approval for <font color="blue">generic drug</font> products, we may     lose <font color="blue">significant</font> <font color="blue">advantages</font> to a <font color="blue">competitor</font> who was first to file an ANDA     containing a <font color="blue">Paragraph IV </font><font color="blue">certification</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font> may  <font color="blue">also pursue legislative</font> and other <font color="blue">regulatory</font> or     <font color="blue"><font color="blue">litigation</font> strategies</font> to prevent or delay our launch of a <font color="blue">generic product</font></td>
    </tr>
    <tr>
      <td>These strategies include, but are not limited to: seeking to obtain new     <font color="blue">patents on drugs</font> for <font color="blue">which patent protection</font> is about to expire, changing     the                                         29       _________________________________________________________________    [73]Table of <font color="blue">Contents       </font>labeling for the <font color="blue">branded product</font>, filing a <font color="blue">citizen petition with</font> the FDA,     pursuing state <font color="blue">legislative efforts</font> to limit the <font color="blue">substitution</font> of generic     versions of brand <font color="blue">pharmaceutical</font>s, filing patent <font color="blue">infringement</font> lawsuits that     <font color="blue">automatically delay</font> FDA approval of many <font color="blue"><font color="blue">generic product</font>s</font>, introducing a     <font color="blue">second <font color="blue">generation</font> product prior</font> to the expiration of <font color="blue">market exclusivity</font> for     the first <font color="blue">generation</font> product, which may reduce demand for a <font color="blue">generic first</font>     <font color="blue">generation</font>  product,  and  obtaining  <font color="blue">market exclusivity</font> extensions by     <font color="blue">conducting pediatric trials</font> of brand drugs</td>
    </tr>
    <tr>
      <td><font color="blue">The European </font>market for our <font color="blue">products may</font> be limited due to <font color="blue">pricing pressures</font>     and other matters</td>
    </tr>
    <tr>
      <td><font color="blue">Pharmaceutical </font>prices, including prices for our products, in Europe and     certain other countries are <font color="blue">significant</font>ly lower than <font color="blue">in the United States</font></td>
    </tr>
    <tr>
      <td>Because our <font color="blue">agreement</font>s with <font color="blue">Novartis Pharma </font>provide for us to receive a     percentage of Novartis Pharma’s <font color="blue">net selling price</font> (subject to a minimum     price), our gross margins are <font color="blue">generally</font> much lower for product sold to     <font color="blue">Novartis Pharma </font>for resale outside of the <font color="blue">United States </font>than for product     sold to Novogyne for sale <font color="blue">in the United States</font></td>
    </tr>
    <tr>
      <td>In addition, the lower     <font color="blue">prices restrict</font> Novartis Pharma’s gross margin realized <font color="blue">from selling</font> our     products</td>
    </tr>
    <tr>
      <td>Because our products compete for sales and <font color="blue">marketing resources</font>     with other <font color="blue">Novartis Pharma </font>products, including <font color="blue">competitive</font> HT products,     there can be no assurance that the <font color="blue"><font color="blue">relatively</font> low</font> gross <font color="blue">margins generated</font>     from  selling our <font color="blue">products will</font> not cause <font color="blue">Novartis Pharma </font>to focus its     resources on other products or even not launch our products in certain     countries</td>
    </tr>
    <tr>
      <td><font color="blue">Novartis Pharma </font>has launched Estradot^^® in the United Kingdom,     France, Germany, Spain (without the benefit of <font color="blue">government</font> <font color="blue">reimbursement</font>) and     in a number of smaller European countries</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> that <font color="blue">Novartis  </font>   Pharma will be successful in launching Estradot^^® in other countries</td>
    </tr>
    <tr>
      <td>The     <font color="blue">profitability</font> of sales in Europe may be <font color="blue"><font color="blue"><font color="blue">negatively</font> affected</font> by</font> parallel     <font color="blue">trade practices</font> in the <font color="blue">European Union </font>whereby a <font color="blue">licensed importer may</font> take     advantage of price disparity between markets by purchasing our products in a     <font color="blue">market with</font> a <font color="blue"><font color="blue">relatively</font> low</font>er price and <font color="blue">then importing them into</font> a country     with  <font color="blue">relatively</font>  higher  price</td>
    </tr>
    <tr>
      <td>Lack of <font color="blue">government</font> <font color="blue">reimbursement</font> for     Estradot^^® <font color="blue">could also</font> <font color="blue">negatively</font> impact the product’s <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>In     addition, <font color="blue">Novartis Pharma </font>has <font color="blue">advised us</font> that they plan to <font color="blue">seek marketing</font>     approval and <font color="blue">commercialization</font> of a <font color="blue">lower dosage strength</font> when and if a next     <font color="blue">generation</font> <font color="blue">combination</font> product is developed</td>
    </tr>
    <tr>
      <td>No assurance can be given that     we   will  complete  <font color="blue">development</font>  of  a  next  <font color="blue">generation</font>  <font color="blue">combination</font>     estrogen/progestin patch or that <font color="blue">approval will</font> be obtained, and the timing     of any launch of a next <font color="blue">generation</font> <font color="blue">combination</font> estrogen/progestin patch     <font color="blue">product cannot</font> be predicted</td>
    </tr>
    <tr>
      <td>We expect that growth in this <font color="blue">market will</font> be     limited unless and until a next <font color="blue">generation</font> <font color="blue">combination</font> estrogen/progestin     <font color="blue">patch product</font> is developed, approved and launched</td>
    </tr>
    <tr>
      <td>Our quarterly operating results are subject to <font color="blue">significant</font> fluctuations</td>
    </tr>
    <tr>
      <td>In 2005, we experienced <font color="blue">significant</font> fluctuations in our quarterly     operating results and we expect that <font color="blue"><font color="blue">revenues from</font> product sales</font> to our     licensees as well as our research and <font color="blue">development</font> <font color="blue"><font color="blue">expenditure</font>s</font> will continue     to fluctuate from quarter-to-quarter and year-to-year depending upon various     factors not in our control, including the <font color="blue">purchasing patterns</font> of wholesale     drug distributors, marketing efforts of <font color="blue">each licensee</font>, fluctuations in sales     and returns <font color="blue">allowances</font>, including those related to <font color="blue">allowances</font> for expiring     <font color="blue">product as well as product recalls</font>, the inventory <font color="blue">requirements</font> of each     licensee,  the impact of <font color="blue">competitive</font> products, the timing and scope of     Estradot^^® launches and <font color="blue">commercialization</font> efforts by Novartis Pharma, the     impact <font color="blue">of the HT </font><font color="blue">studies on prescriptions</font> for our HT products, the product     pricing of <font color="blue">each licensee</font>, the timing of <font color="blue">certain royalty reconciliations</font> and     <font color="blue">payments under</font> our license <font color="blue">agreement</font>s, the timing of FDA approval, including     for Daytrana^™, and any <font color="blue">subsequent launch</font> of <font color="blue">new products</font>, and the success     of Shire’s <font color="blue">commercialization</font> efforts</td>
    </tr>
    <tr>
      <td>Our <font color="blue">earnings may fluctuate</font> because of,     among other things, fluctuations in research and <font color="blue">development</font>                                         30       _________________________________________________________________    [74]Table of <font color="blue">Contents       </font>spending resulting from the timing of <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">Novartis  </font>   is entitled to an annual dlra6dtta1 million preferred return, which has the effect     of reducing our share of Novogyne’s income in the <font color="blue">first quarter</font> of each     year</td>
    </tr>
    <tr>
      <td>Our results of <font color="blue">operations</font> will be <font color="blue">adversely</font> affected if we or Novogyne fail     to realize the full value of our <font color="blue">intangible assets</font></td>
    </tr>
    <tr>
      <td><font color="blue">Accounting </font>principles <font color="blue">generally</font> accepted in the <font color="blue">United States </font>require     Novogyne and us to test the <font color="blue">recoverability</font> of our respective long-lived     assets and certain <font color="blue">identifiable</font> <font color="blue">intangible assets</font> whenever events or changes     in <font color="blue">circumstances</font> indicate that those assets’ carrying amount may not be     recoverable</td>
    </tr>
    <tr>
      <td>Novogyne recorded the     <font color="blue">acquisition</font> of the CombiPatch^^® <font color="blue">product marketing rights at cost</font> and tests     this asset for <font color="blue">impairment on</font> a <font color="blue">periodic basis</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">further adverse</font> change in     the  market  for HT products or a recall of CombiPatch^^® could have a     material <font color="blue">adverse impact on</font> the ability <font color="blue">of Novogyne </font>to recover its <font color="blue">investment</font>     in its CombiPatch^^® marketing rights, <font color="blue">which could</font> require Novogyne to     revalue  that  asset</td>
    </tr>
    <tr>
      <td><font color="blue">Impairment </font>of that asset would <font color="blue">adversely</font> affect     Novogyne’s, and <font color="blue">consequently</font> our, operating results</td>
    </tr>
    <tr>
      <td>We cannot be certain of the protection or <font color="blue">confidentiality</font> of our patents and     <font color="blue"><font color="blue">proprietary</font> rights</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will depend</font>, in part, on our ability to obtain or license     patents for our products, processes and <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>If we do not do so,     our <font color="blue"><font color="blue">competitor</font>s</font> may exploit our <font color="blue">innovations</font> and <font color="blue">deprive us</font> of the ability to     realize <font color="blue">revenues from</font> those <font color="blue">innovations</font></td>
    </tr>
    <tr>
      <td>There is no assurance that we will     be <font color="blue">issued patents</font> for any of our patent <font color="blue">application</font>s, that any existing or     future  patents  that  we  receive or license will provide <font color="blue">competitive</font>     <font color="blue">advantages</font> for our products, or that we will be able to enforce <font color="blue">successfully</font>     our <font color="blue">patent rights</font></td>
    </tr>
    <tr>
      <td>Additionally, there can be no assurance that our patents     or any <font color="blue">future patents</font> will prevent other <font color="blue">companies from</font> developing similar     or  <font color="blue">functionally</font>  <font color="blue">equivalent products</font>, or challenging, invalidating or     avoiding our patent <font color="blue">application</font>s or any existing or <font color="blue">future patents</font> that we     receive or license</td>
    </tr>
    <tr>
      <td>Many of our patents are <font color="blue">formulation</font> patents and would     not preclude others from developing and marketing products that deliver     drugs  <font color="blue">transdermally</font> or otherwise through non-infringing <font color="blue">formulation</font>s</td>
    </tr>
    <tr>
      <td>Furthermore, there is no assurance that any of our <font color="blue">future processes</font> or     <font color="blue">products will</font> be patentable, that any pending or <font color="blue">additional</font> patents will be     issued in any or all <font color="blue">appropriate jurisdictions</font> or that our processes or     <font color="blue">products will</font> not <font color="blue">infringe upon</font> the patents of <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>We also rely on <font color="blue">trade secrets</font>, unpatented <font color="blue">proprietary</font> know-how and     continuing <font color="blue">technological</font> innovation</td>
    </tr>
    <tr>
      <td>We use <font color="blue">confidentiality</font> <font color="blue">agreement</font>s with     licensees,  suppliers,  employees and <font color="blue">consultants</font> to protect our trade     secrets,  unpatented <font color="blue">proprietary</font> know-how and continuing <font color="blue">technological</font>     innovation, but there can be no assurance that these <font color="blue">parties will</font> not breach     their <font color="blue">agreement</font>s with us or that we will be able to <font color="blue">effective</font>ly enforce our     <font color="blue">rights under</font> those <font color="blue">agreement</font>s</td>
    </tr>
    <tr>
      <td>We <font color="blue">also cannot</font> be certain that we will have     adequate  remedies  for  any breach</td>
    </tr>
    <tr>
      <td>Disputes may arise <font color="blue">concerning</font> the     ownership of <font color="blue">intellectual</font> property or the <font color="blue">applicability</font> of <font color="blue">confidentiality</font>     <font color="blue">agreement</font>s</td>
    </tr>
    <tr>
      <td>Furthermore, we cannot be sure that our <font color="blue">trade secrets</font> and     <font color="blue">proprietary</font>  <font color="blue">technology</font>  will  not  <font color="blue">otherwise become known</font> or that our     <font color="blue"><font color="blue">competitor</font>s</font> will not in<font color="blue">dependent</font>ly develop our <font color="blue">trade secrets</font> and <font color="blue">proprietary</font>     <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>31       _________________________________________________________________    [75]Table of <font color="blue">Contents       </font>Third <font color="blue">parties may</font> claim that we infringe their <font color="blue"><font color="blue">proprietary</font> rights</font>, forcing     us to expend substantial resources in resulting <font color="blue">litigation</font>, the outcome of     which is uncertain</td>
    </tr>
    <tr>
      <td>Any unfavorable outcome could <font color="blue">negatively</font> affect our     <font color="blue">financial position</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our  success  depends, in part, on our ability to operate without     infringing the <font color="blue"><font color="blue">proprietary</font> rights</font> of others, and there can be no assurance     that  our products and <font color="blue">processes will</font> not <font color="blue">infringe upon</font> the patents of     others</td>
    </tr>
    <tr>
      <td>Third <font color="blue">parties may</font> also institute patent <font color="blue">litigation</font> against us for     <font color="blue">competitive</font> reasons unrelated to any <font color="blue"><font color="blue">infringement</font> by us</font></td>
    </tr>
    <tr>
      <td>If a <font color="blue">third party</font>     asserts  a claim of <font color="blue">infringement</font>, we may have to seek licenses, defend     <font color="blue">infringement</font> actions or challenge the validity of those third-party patents     in court</td>
    </tr>
    <tr>
      <td>If we cannot obtain the required licenses, or are <font color="blue">found liable</font> for     <font color="blue">infringement</font> or are not able to have these patents declared invalid, we may     be liable for <font color="blue">significant</font> monetary damages, encounter <font color="blue">significant</font> delays in     bringing  products to market or be <font color="blue">precluded from participating</font> in the     <font color="blue">manufacture</font>, use or sale of products or methods of <font color="blue">drug delivery covered by</font>     the patents of others</td>
    </tr>
    <tr>
      <td>There can be no assurance that we have identified, or     that in the future we will be able to identify, all US and foreign patents     that may pose a risk of potential <font color="blue">infringement</font> claims</td>
    </tr>
    <tr>
      <td>We may experience <font color="blue">reductions</font> in the levels of <font color="blue">reimbursement</font> for our products     by  <font color="blue">government</font>al <font color="blue">authorities</font>, private health insurers and <font color="blue">managed care</font>     <font color="blue">organizations</font></td>
    </tr>
    <tr>
      <td>Our ability and our <font color="blue">marketing partners</font>’ ability to <font color="blue">commercialize</font> our     products,  including  Daytrana^™,  is  <font color="blue">dependent</font>  in part on obtaining     <font color="blue">reimbursement</font> from <font color="blue">government</font> health <font color="blue">authorities</font>, private health insurers     and <font color="blue">managed care</font> <font color="blue">organizations</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">trend toward managed healthcare</font> in the     <font color="blue">United States </font>and the prominence of health maintenance <font color="blue">organizations</font> (HMOs)     and similar entities could <font color="blue">significant</font>ly influence the purchase of our     products, resulting in lower prices and lower demand</td>
    </tr>
    <tr>
      <td>This is <font color="blue">particularly</font>     true  in a market that includes generic <font color="blue">alternative</font>s, such as the <font color="blue">ADHD     </font>market</td>
    </tr>
    <tr>
      <td>There  can  be no assurance that Shire will obtain acceptable     <font color="blue">reimbursement</font> status for Daytrana^™</td>
    </tr>
    <tr>
      <td>There can also be no assurance that     <font color="blue">managed care</font> <font color="blue">agreement</font>s established by Novartis will not <font color="blue">adversely</font> affect     Novogyne’s financial results</td>
    </tr>
    <tr>
      <td>Health <font color="blue">care reform</font> or other changes in <font color="blue">government</font> regulation could harm our     business</td>
    </tr>
    <tr>
      <td>The federal and state <font color="blue">government</font>s <font color="blue">in the United States</font>, as well as many     foreign <font color="blue">government</font>s, from time to time <font color="blue">explore ways</font> to <font color="blue">reduce medical care</font>     costs through health <font color="blue">care reform</font></td>
    </tr>
    <tr>
      <td>In the United States, some parties have     advocated for the re-importation of <font color="blue">prescription drugs from</font> Canada and other     countries for re-sale in the <font color="blue">United States </font>at a discount to <font color="blue">United States </font>    prices</td>
    </tr>
    <tr>
      <td>Due to the <font color="blue">diverse range</font> of <font color="blue">proposals put forth</font> from country to     country and the <font color="blue">uncertainty</font> of any proposal’s adoption, we <font color="blue">cannot predict</font>     what  impact  any  reform  <font color="blue">proposal ultimately adopted may</font> have on the     <font color="blue">pharmaceutical</font> industry or on our business, <font color="blue">financial position</font> or results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We may be exposed to <font color="blue">product <font color="blue">liability</font></font> claims and there can be no assurance     of <font color="blue">adequate insurance</font></td>
    </tr>
    <tr>
      <td>Like all <font color="blue">pharmaceutical</font> companies, the testing, <font color="blue">manufacturing</font> and     marketing of our <font color="blue">products may</font> expose us to potential <font color="blue">product <font color="blue">liability</font></font> and     other claims resulting from their use</td>
    </tr>
    <tr>
      <td>We have <font color="blue">been named as</font> a <font color="blue">defendant</font> in     one case in which a plaintiff alleges <font color="blue">personal injury from</font> the use of HT     products,  including  Vivelle^^®,  which  we  <font color="blue">manufacture</font> and <font color="blue">Novogyne     </font><font color="blue">distributes</font></td>
    </tr>
    <tr>
      <td>In addition, Novartis has <font color="blue">advised us</font> that Novartis has been     named  as  a  <font color="blue">defendant</font>  in  at least 16 <font color="blue">additional</font> lawsuits involving     <font color="blue">approximately</font>  21  plaintiffs that allege <font color="blue">liability</font> in <font color="blue">connection with</font>     personal  injury  claims  <font color="blue">allegedly</font> arising from the use of HT patches     <font color="blue">distributed</font> and sold by Novartis and Novogyne, including our products,     Vivelle-Dot^™, Vivelle^^® and CombiPatch^^®</td>
    </tr>
    <tr>
      <td>If any such claims against us     are successful, we may be required to make <font color="blue">significant</font> <font color="blue">compensation</font> payments     and suffer the associated adverse publicity</td>
    </tr>
    <tr>
      <td>Even <font color="blue">unsuccessful</font> claims could     result  in the <font color="blue">expenditure</font> of funds in <font color="blue">litigation</font> and the diversion of     <font color="blue">management</font> time and resources</td>
    </tr>
    <tr>
      <td>We maintain <font color="blue">product <font color="blue">liability</font></font> insurance, but     there                                         32       _________________________________________________________________    [76]Table of <font color="blue">Contents       </font>can be no assurance that our <font color="blue">insurance will cover</font> all future claims or that     we will be able to maintain <font color="blue">existing coverage</font> or obtain <font color="blue">additional</font> coverage     at  <font color="blue">reasonable rates</font></td>
    </tr>
    <tr>
      <td>Over the past few years, the cost of our product     <font color="blue">liability</font> insurance policy has increased while providing <font color="blue">significant</font>ly less     coverage and higher <font color="blue">deductibles</font> than in the past</td>
    </tr>
    <tr>
      <td>If a claim is not covered     or if our coverage is insufficient, we may incur <font color="blue">significant</font> <font color="blue">liability</font>     payments that would <font color="blue">negatively</font> affect our business, <font color="blue">financial position</font> or     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>All of our products are <font color="blue">manufacture</font>d at one location</td>
    </tr>
    <tr>
      <td>An <font color="blue">interruption</font> of     <font color="blue">production at</font> this <font color="blue">facility</font> could <font color="blue">negatively</font> affect our business, financial     position and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>All of our products are <font color="blue">manufacture</font>d at a single <font color="blue">facility</font> in Miami,     Florida</td>
    </tr>
    <tr>
      <td>An <font color="blue">interruption</font> of <font color="blue">manufacturing</font> resulting from <font color="blue">regulatory</font> issues,     technical problems, <font color="blue">casualty loss</font> (including hurricane) or other factors     could result in our <font color="blue">inability</font> to meet production <font color="blue">requirements</font>, which may     cause us to <font color="blue">lose revenues</font> and <font color="blue">which could</font> have an adverse effect on our     <font color="blue">relationships with</font> our partners and customers, any of <font color="blue">which could</font> have a     material adverse effect on our business, <font color="blue">financial position</font> or results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Without our existing production <font color="blue">facility</font>, we would have no other     means  of <font color="blue">manufacturing</font> our <font color="blue">products until</font> we were able to restore the     <font color="blue">manufacturing</font>  <font color="blue">capability</font>  at  our  <font color="blue">facility</font> or develop an <font color="blue">alternative</font>     <font color="blue">manufacturing</font> <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>Although we carry business <font color="blue">interruption</font> insurance to     cover  lost  revenues and profits resulting <font color="blue">from <font color="blue">casualty loss</font>es</font>, this     insurance  does not cover all <font color="blue">possible situations</font> and cannot cover all     <font color="blue">potential exposure</font> and there can be no assurance that any event of casualty     to  our  <font color="blue">facility</font> would be <font color="blue">covered by such insurance</font></td>
    </tr>
    <tr>
      <td>In addition, our     business <font color="blue">interruption</font> insurance would not <font color="blue">compensate us</font> for the loss of     <font color="blue">opportunity</font> and potential <font color="blue">adverse impact on</font> relations with our existing     partners and customers resulting from our <font color="blue">inability</font> to produce products for     them</td>
    </tr>
    <tr>
      <td>We <font color="blue">use <font color="blue"><font color="blue">hazardous</font> chemicals</font></font> in our business</td>
    </tr>
    <tr>
      <td><font color="blue">Potential </font>claims relating to     improper handling, storage or disposal of these <font color="blue">chemicals could</font> be time     consuming and costly</td>
    </tr>
    <tr>
      <td>Our research and <font color="blue">development</font> processes involve the <font color="blue">controlled use</font> of     <font color="blue"><font color="blue">hazardous</font> chemicals</font></td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">hazardous</font> chemicals</font> are reagents and solvents     <font color="blue">typically found</font> in a <font color="blue">chemistry laboratory</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">operations</font> also produce     <font color="blue"><font color="blue">hazardous</font> waste products</font></td>
    </tr>
    <tr>
      <td>Federal, state and <font color="blue">local laws</font> and <font color="blue">regulations</font>     govern the use, <font color="blue">manufacture</font>, storage, handling and disposal of <font color="blue">hazardous</font>     materials</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot eliminate</font> all risk of <font color="blue">accidental contamination from</font> or     discharge of <font color="blue">hazardous</font> materials and any <font color="blue">resultant injury</font></td>
    </tr>
    <tr>
      <td><font color="blue">Compliance </font>with     <font color="blue">environmental laws</font> and <font color="blue">regulations</font> may be expensive</td>
    </tr>
    <tr>
      <td>We might have to pay     <font color="blue">civil damages</font> in the event of an improper or <font color="blue">unauthorized release</font> of, or     exposure of <font color="blue">individuals</font> to, <font color="blue">hazardous</font> materials</td>
    </tr>
    <tr>
      <td>We are not <font color="blue">insured against</font>     these <font color="blue">environmental risks</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">operations</font> could be disrupted if our information <font color="blue">systems fail</font> or if we     are <font color="blue">unsuccessful</font> in implementing <font color="blue">necessary</font> upgrades</td>
    </tr>
    <tr>
      <td>Our business <font color="blue">depends on</font> the <font color="blue">efficient</font> and <font color="blue">uninterrupted operation</font> of     our computer and <font color="blue">communications software</font> and <font color="blue">hardware systems</font>, and our other     information  <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>In the coming years, we may have to implement     <font color="blue">significant</font>   upgrades  to  our  information  systems,  including  the     <font color="blue">implementation</font> and <font color="blue">qualification</font> of an upgrade to our business <font color="blue">application</font>s     software</td>
    </tr>
    <tr>
      <td>If our systems were to fail or we are unable to <font color="blue">successfully</font>     expand the <font color="blue">capacity</font> of these systems or to integrate new <font color="blue">technologies</font> into     our <font color="blue">existing systems</font>, our <font color="blue">operations</font> and financial results <font color="blue">could suffer</font></td>
    </tr>
    <tr>
      <td>33       _________________________________________________________________    [77]Table of <font color="blue">Contents       </font>Our <font color="blue"><font color="blue">insurance coverage</font> may</font> not be adequate and <font color="blue">rising insurance premiums</font>     could <font color="blue">negatively</font> affect our <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">rely on insurance</font> to <font color="blue">protect us from</font> many business risks, including     product  <font color="blue">liability</font>, business <font color="blue">interruption</font>, property and <font color="blue">casualty loss</font>,     <font color="blue">employment</font> practices <font color="blue">liability</font> and <font color="blue">directors</font>’ and officers’ <font color="blue">liability</font></td>
    </tr>
    <tr>
      <td>The     cost  of  insurance  has risen <font color="blue">significant</font>ly in the <font color="blue">last few years</font></td>
    </tr>
    <tr>
      <td>There can be no assurance that the insurance that we     maintain  and intend to maintain will be adequate, or that the cost of     insurance  and  <font color="blue">limitations</font>  in <font color="blue">coverage will</font> not <font color="blue">adversely</font> affect our     business, <font color="blue">financial position</font> or results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Furthermore, it is     possible that, in some cases, coverage may not be <font color="blue">available at</font> any price</td>
    </tr>
    <tr>
      <td>Our <font color="blue">financial position</font> and results of <font color="blue">operations</font> could be harmed if we are     required to perform <font color="blue">under existing</font> or <font color="blue">future contractual <font color="blue">indemnification</font></font>     provisions</td>
    </tr>
    <tr>
      <td>In the normal course of business, we enter into <font color="blue">development</font>, license,     supply,  <font color="blue">employment</font>  and other <font color="blue">agreement</font>s that include <font color="blue">indemnification</font>     provisions</td>
    </tr>
    <tr>
      <td><font color="blue">The Novogyne </font><font color="blue">joint venture</font> operating <font color="blue">agreement</font> contains an     <font color="blue">indemnification</font>  <font color="blue">provision as</font> do <font color="blue">certain supply</font> and license <font color="blue">agreement</font>s     between and among Noven, Novartis and Novogyne</td>
    </tr>
    <tr>
      <td>The various <font color="blue">indemnification</font>     provisions  in  these <font color="blue">agreement</font>s are not uniform and, <font color="blue">depending on</font> the     <font color="blue">circumstances</font>, may be subject to differing <font color="blue">legal interpretations</font></td>
    </tr>
    <tr>
      <td>As a     consequence,  it  may  be <font color="blue">difficult</font> in certain <font color="blue">circumstances</font> for us to     determine or predict in advance what <font color="blue">indemnification</font> <font color="blue">obligations</font> Noven may     owe to Novogyne or Novartis under these provisions or, <font color="blue">alternative</font>ly, what     <font color="blue">obligations</font> may be owed to Noven by these parties, including as they relate     to potential damages, settlement amounts and <font color="blue">defense costs associated with</font>     the <font color="blue">product <font color="blue">liability</font></font> lawsuits that claim the use of products we <font color="blue">manufacture</font>     and Novogyne <font color="blue">distributes</font></td>
    </tr>
    <tr>
      <td>While <font color="blue"><font color="blue">insurance coverage</font> may</font> mitigate the costs of     some of our <font color="blue">obligations</font> under our <font color="blue">indemnification</font> provisions, our business,     <font color="blue">financial position</font> and results of <font color="blue">operations</font> could be harmed if we are     required to perform under these <font color="blue">indemnification</font> provisions and there is no     or insufficient <font color="blue">insurance coverage</font></td>
    </tr>
    <tr>
      <td>Our success <font color="blue">depends on</font> attracting and retaining our <font color="blue">key employees</font></td>
    </tr>
    <tr>
      <td>Our success <font color="blue">depends on</font> our ability to attract and retain qualified,     experienced  personnel</td>
    </tr>
    <tr>
      <td>We face <font color="blue">significant</font> <font color="blue">competition</font> in recruiting     <font color="blue">talented personnel</font></td>
    </tr>
    <tr>
      <td>In the past, our location in an area with <font color="blue">relatively</font> few     <font color="blue">pharmaceutical</font>  companies has made <font color="blue">recruitment</font> more <font color="blue">difficult</font>, as many     <font color="blue">candidates prefer</font> to work in <font color="blue">places with</font> a broad <font color="blue">pharmaceutical</font> industry     presence</td>
    </tr>
    <tr>
      <td>The loss of <font color="blue">key personnel</font>, or the <font color="blue">inability</font> to attract and retain     <font color="blue">additional</font>,  competent employees, could <font color="blue">adversely</font> affect our business,     <font color="blue">financial position</font> or results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">stockholders</font>’ rights plan, our <font color="blue">charter documents</font>, <font color="blue">Delaware </font>law and our     <font color="blue">joint venture</font> with Novartis may have an anti-takeover effect</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">stockholders</font>’  rights plan, our corporate <font color="blue">charter documents</font>,     <font color="blue">Delaware </font>law and our <font color="blue">joint venture</font> operating <font color="blue">agreement</font> with Novartis each     include provisions that <font color="blue">may discourage</font> or <font color="blue">prevent parties from attempting</font> to     acquire  us</td>
    </tr>
    <tr>
      <td>These  provisions  may  have the effect of depriving our     <font color="blue">stockholders</font> of the <font color="blue">opportunity</font> to sell their stock at a price in excess of     <font color="blue">prevailing <font color="blue">market price</font>s</font> in an <font color="blue">acquisition</font> of us</td>
    </tr>
    <tr>
      <td>We have a <font color="blue">stockholders</font>’     rights plan, <font color="blue">commonly referred</font> to as a “poison pill,” which is intended to     cause substantial dilution to a person or group who attempts to acquire us     on terms that our <font color="blue"><font color="blue">Board of Directors</font> </font>has not approved</td>
    </tr>
    <tr>
      <td>The existence of the     <font color="blue">stockholders</font>’ rights plan could make it more <font color="blue">difficult</font> for a <font color="blue">third party</font> to     acquire a majority of our <font color="blue"><font color="blue">common stock</font> without</font> the consent of our Board of     Directors</td>
    </tr>
    <tr>
      <td>Certain provisions of our <font color="blue">certificate</font> of <font color="blue">incorporation</font> and bylaws     could have the effect of making it                                         34       _________________________________________________________________    [78]Table of <font color="blue">Contents       </font>more <font color="blue">difficult</font> for a <font color="blue">third party</font> to acquire a majority of our outstanding     <font color="blue">voting <font color="blue">common stock</font></font></td>
    </tr>
    <tr>
      <td>These include provisions that limit the ability of     <font color="blue">stockholders</font> to <font color="blue">bring matters</font> before an <font color="blue">annual meeting</font> of <font color="blue">stockholders</font>, call     <font color="blue">special meetings</font> or <font color="blue">nominate candidates</font> to serve on our <font color="blue">Board of Directors</font></td>
    </tr>
    <tr>
      <td>We are also subject to the provisions of Section 203 of the <font color="blue">Delaware </font>    General  Corporation  Law,  which  prohibits  a publicly-held <font color="blue">Delaware </font>    <font color="blue">corporation from</font> engaging in a “business <font color="blue">combination</font>” with an “interested     stockholder” for a period of <font color="blue">three years</font> after the date of the <font color="blue">transaction</font>     in which the person became an <font color="blue">interested stockholder</font>, unless the business     <font color="blue">combination</font> is approved in a <font color="blue">prescribed manner</font></td>
    </tr>
    <tr>
      <td>For purposes of Section 203,     a “business <font color="blue">combination</font>” includes a merger, asset sale or other <font color="blue">transaction</font>     resulting in a <font color="blue">financial benefit</font> to the <font color="blue">interested stockholder</font>, and an     “<font color="blue">interested stockholder</font>” is a person who, <font color="blue">either alone</font> or <font color="blue">together with</font>     <font color="blue">affiliates</font> and <font color="blue">associates</font>, owns (or within the past <font color="blue">three years</font>, did own)     15prca or more of the corporation’s voting stock</td>
    </tr>
    <tr>
      <td>The operating <font color="blue">agreement</font> for our <font color="blue">joint venture</font> with Novartis has a     buy/sell provision that either party <font color="blue">may trigger by notifying</font> the other     party of the <font color="blue">price at which</font> the <font color="blue">triggering party would</font> be willing to acquire     the other party’s interest in the <font color="blue">joint venture</font></td>
    </tr>
    <tr>
      <td>As a result of the buy/sell     provision, any <font color="blue">potential acquirer</font> of us faces the <font color="blue">possibility</font> that <font color="blue">Novartis  </font>   <font color="blue">could trigger</font> this <font color="blue">provision at</font> any time and thereby require the acquirer to     <font color="blue">either purchase</font> for cash Novartis’ interest in Novogyne (<font color="blue">which would</font> include     the <font color="blue">net present value</font> of Novartis’ dlra6dtta1 million annual preferred return) or     to sell its interest in <font color="blue">Novogyne to Novartis</font></td>
    </tr>
    <tr>
      <td>The existence of the buy/sell     provision and the <font color="blue">uncertainty</font> it may create <font color="blue">could discourage</font> an <font color="blue">acquisition</font>     of us by a <font color="blue">third party</font>, <font color="blue">which could</font> have an adverse effect on the market     price for our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>In addition, the operating <font color="blue">agreement</font> gives     Novartis the right to dissolve the <font color="blue">joint venture</font> in the event of a change in     control of Noven if the acquirer is one of the ten largest <font color="blue">pharmaceutical</font>     companies (as measured by annual dollar sales)</td>
    </tr>
    <tr>
      <td>Upon <font color="blue">dissolution</font>, <font color="blue">Novartis  </font>   would reacquire the rights to market Vivelle-Dot^™ and Vivelle^^® subject to     the terms of Novartis’ <font color="blue">prior arrangement with us</font>, and Novogyne’s other     assets would be liquidated and <font color="blue">distributed</font> to the parties in <font color="blue">accordance</font> with     their <font color="blue">capital account balances as</font> determined pursuant to the <font color="blue">joint venture</font>     operating <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">dissolution</font> provision could have an anti-takeover     effect <font color="blue">with respect</font> to a top ten <font color="blue">pharmaceutical</font> company</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> for our <font color="blue">common stock</font> is volatile</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of our <font color="blue">common stock</font> is volatile</td>
    </tr>
    <tr>
      <td>Any number of factors, including some over which we have no control     and  some  unrelated  to our business or financial results, may have a     <font color="blue">significant</font> impact on the <font color="blue">market price</font> of our <font color="blue">common stock</font>, including:     <font color="blue">announcements by us</font> or our <font color="blue"><font color="blue">competitor</font>s</font> of <font color="blue">technological</font> <font color="blue">innovations</font> or new     <font color="blue">commercial products</font>, changes in <font color="blue">government</font>al regulation, receipt by us or     one  of  our <font color="blue"><font color="blue">competitor</font>s</font> of <font color="blue"><font color="blue">regulatory</font> approval</font>s or adverse <font color="blue">regulatory</font>     <font color="blue">determination</font>s, <font color="blue">development</font>s relating to our patents or <font color="blue"><font color="blue">proprietary</font> rights</font>     of one of our <font color="blue"><font color="blue">competitor</font>s</font>, publicity regarding actual or <font color="blue">potential medical</font>     results or risks for products that we or one of our <font color="blue"><font color="blue">competitor</font>s</font> market or     has under <font color="blue">development</font>, and period-to-period changes in financial results and     the economy <font color="blue">generally</font></td>
    </tr>
    <tr>
      <td>We, like any other <font color="blue">company with</font> a <font color="blue">volatile stock</font>     price, may be subject to further securities <font color="blue">litigation</font>, <font color="blue">which could</font> have a     material adverse effect on our business and financial results</td>
    </tr>
  </tbody>
</table>